News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 7, 2023

Strategies to Manage Medication Costs and Waste

Russell P. Gollard, MD, FACP, discusses strategies for mitigating the high costs of expensive medications, addressing concerns of medication waste and hoarding.

Episodes in this series

EP. 1 Management Insights for Patients With Hemophilia

EP. 1 Management Insights for Patients With Hemophilia

EP. 2 Coverage Decisions for Expensive Hemophilia Treatments

EP. 2 Coverage Decisions for Expensive Hemophilia Treatments

EP. 3 Impact of ICER Reports on Hemophilia Treatment Decisions

EP. 3 Impact of ICER Reports on Hemophilia Treatment Decisions

EP. 4 Enhancing Provider Access and Expertise for Rare Disease Care

EP. 4 Enhancing Provider Access and Expertise for Rare Disease Care

EP. 5 Factors Impacting Hemophilia A Care Costs

EP. 5 Factors Impacting Hemophilia A Care Costs

EP. 6 Collaborative Strategies in Hemophilia A Care Cost Management

EP. 6 Collaborative Strategies in Hemophilia A Care Cost Management

EP. 7 Strategies to Manage Medication Costs and Waste

EP. 7 Strategies to Manage Medication Costs and Waste

EP. 8 Adapting to Novel Hemophilia A Treatments

EP. 8 Adapting to Novel Hemophilia A Treatments

EP. 9 Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP. 9 Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP. 10 Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP. 10 Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP. 11 Hemophilia A Treatment Factors and Outcomes

EP. 11 Hemophilia A Treatment Factors and Outcomes

EP. 12 Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP. 12 Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP. 13 Consequences of Nonadherence in Hemophilia A

EP. 13 Consequences of Nonadherence in Hemophilia A

EP. 14 Advancements in Hemophilia A Therapies

EP. 14 Advancements in Hemophilia A Therapies

EP. 15 Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP. 15 Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP. 16 Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP. 16 Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP. 17 Emicizumab Dosing: Prophylaxis and Bleeding Management

EP. 17 Emicizumab Dosing: Prophylaxis and Bleeding Management

EP. 18 Optimizing Hemophilia Treatment: Strategies and Adherence

EP. 18 Optimizing Hemophilia Treatment: Strategies and Adherence

EP. 19 Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP. 19 Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP. 20 Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

EP. 20 Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

Additional Emerging HER2-Targeted Therapies in NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

5 experts are featured in this series

Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP

February 3rd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text